Related Experiment Video
Updated: Aug 19, 2026
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation
C Libetta1, L De Nicola, T Rampino
1Department of Nephrology, University "Federico II" of Naples, Italy.
Abstract:
We evaluated in peritonitis-free patients undergoing continuous ambulatory peritoneal dialysis (CAPD) the release of both interleukin-6 (IL-6) and beta-2-microglobulin (beta 2m) by cultured peripheral blood mononuclear cells (PBMC), as well as the levels of serum amyloid A (SAA), that is, the main hepatic acute phase protein during inflammation. The same measurements were obtained in hemodialysis (HD) patients, uremic non-dialyzed patients (ESRD) and healthy controls (CON). In CAPD, IL-6 production from PBMC was markedly increased in comparison to the control value (600.7 +/- 104.3 vs. 14.2 +/- 3.6 pg/3 x 10(6) PBMC/24 hr, P < 0.005). Similarly, a striking enhancement of the PBMC release of beta 2m was detected in CAPD with respect to CON (10.1 +/- 2.6 vs. 0.063 +/- 0.013 micrograms/3 x 10(6) PBMC/24 hr, P < 0.001). Also, the SAA levels were significantly greater in CAPD patients (21.3 +/- 8.7 micrograms/dl) than in controls (3.14 +/- 0.17 micrograms/dl, P < 0.05). Analogous increases of both IL-6 and beta 2m cell releases, as well as of SAA levels, were observed in HD patients. No difference concerning the three parameters was detected between CON and ESRD. In conclusion, CAPD induces per se PBMC activation with an enhanced release of both IL-6 and beta 2m; this is associated to higher levels of SAA. These systemic inflammatory effects are comparable to those observed in HD patients indicating that CAPD is similar to HD in terms of biocompatibility of the treatment.
Insights
Continuous ambulatory peritoneal dialysis (CAPD) activates peripheral blood mononuclear cells (PBMC), increasing interleukin-6 (IL-6) and beta-2-microglobulin (beta 2m) release and serum amyloid A (SAA) levels, similar to hemodialysis (HD).
Area of Science:
- Nephrology
- Immunology
- Biochemistry
Background:
- Patients undergoing renal replacement therapy exhibit altered inflammatory markers.
- Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are common treatments for end-stage renal disease (ESRD).
- The systemic inflammatory response in CAPD patients requires further elucidation.
Purpose of the Study:
- To evaluate the release of interleukin-6 (IL-6) and beta-2-microglobulin (beta 2m) from peripheral blood mononuclear cells (PBMC) in CAPD patients.
- To measure serum amyloid A (SAA) levels in CAPD patients.
- To compare these inflammatory markers between CAPD, HD, ESRD, and healthy controls (CON).
Main Methods:
- Cultured peripheral blood mononuclear cells (PBMC) from peritonitis-free CAPD patients, HD patients, ESRD patients, and healthy controls.
- Measurement of IL-6 and beta 2m release from PBMC.
- Quantification of serum amyloid A (SAA) levels.
Main Results:
- CAPD patients showed significantly increased IL-6 and beta 2m release from PBMC compared to controls.
- SAA levels were significantly elevated in CAPD patients versus controls.
- Similar increases in IL-6, beta 2m, and SAA were observed in HD patients; no differences were found between CON and ESRD patients.
Conclusions:
- CAPD induces peripheral blood mononuclear cell (PBMC) activation, leading to enhanced release of IL-6 and beta 2m.
- This PBMC activation is associated with elevated serum amyloid A (SAA) levels in CAPD patients.
- The systemic inflammatory effects of CAPD are comparable to those of HD, suggesting similar biocompatibility.
Related Concept Videos
01:30Peritoneal Dialysis I: Introduction and Procedure
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications